Vera Therapeutics, Inc.

NasdaqGM VERA

Vera Therapeutics, Inc. Market Capitalization on January 14, 2025: USD 2.19 B

Vera Therapeutics, Inc. Market Capitalization is USD 2.19 B on January 14, 2025, a 154.28% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Vera Therapeutics, Inc. 52-week high Market Capitalization is USD 3.17 B on December 04, 2024, which is 44.79% above the current Market Capitalization.
Vera Therapeutics, Inc. 52-week low Market Capitalization is USD 764.49 M on January 18, 2024, which is -65.10% below the current Market Capitalization.
Vera Therapeutics, Inc. average Market Capitalization for the last 52 weeks is USD 2.36 B.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGM: VERA

Vera Therapeutics, Inc.

CEO	Dr. Marshall W. Fordyce M.D.
IPO Date	May 14, 2021
Location	United States
Headquarters	8000 Marina Boulevard
Employees	82
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Key trends

Past 5 years